Latest Breaking News On - Regen biopharma - Page 20 : comparemela.com

Oncology Pharma Inc : Oncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon Cancer

(1) SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) ONPH has entered into a licensing agreement with Regen BioPharma, Inc. for a technology utilizing small molecules to activate immune checkpoints for the treatment of colon cancer. The program entails identifying small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially critical immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, one can unleash the cancer-killing potential of a patient s own immune system. Regen is also engaged in the identification of small molecules which activate the NR2F6 nuclear receptor that can be utilized to develop small molecule therapies for autoimmune disorders.

San franciscoUnited statesKostenloser wertpapierhandelRegen biopharmaRegen biopharma incOncology pharma incOncology pharmaAdvisory boardSansome streetசான் பிரான்சிஸ்கோஒன்றுபட்டது மாநிலங்களில்புற்றுநோயியல் பார்மா இன்க்புற்றுநோயியல் பார்மா

Oncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon Cancer

Oncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon Cancer ACCESSWIRE SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) ONPH has entered into a licensing agreement with Regen BioPharma, Inc. for a technology utilizing small molecules to activate immune checkpoints for the treatment of colon cancer. The program entails identifying small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially critical immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, one can unleash the cancer-killing potential of a patient s own immune system. Regen is also engaged in the identification of small molecules which activate the NR2F6 nuclear receptor that can be utilized to develop small molecule therapies for autoimmune disorders.

San franciscoUnited statesRegen biopharmaRegen biopharma incOncology pharma incOncology pharmaAdvisory boardSansome streetசான் பிரான்சிஸ்கோஒன்றுபட்டது மாநிலங்களில்புற்றுநோயியல் பார்மா இன்க்புற்றுநோயியல் பார்மா

Oncology Pharma, Inc Addresses Pancreatic Cancer, the Need for an Effective Therapy and the Potential of mRNA Technology

Oncology Pharma, Inc Addresses Pancreatic Cancer, the Need for an Effective Therapy and the Potential of mRNA Technology
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoRegen biopharma incOncology pharma incNational cancer instituteA spokesperson for the companyOncology pharmaRegen biopharmaPancreatic cancerAdvisory boardSansome streetஒன்றுபட்டது மாநிலங்களில்சான் பிரான்சிஸ்கோபுற்றுநோயியல் பார்மா இன்க்தேசிய புற்றுநோய் நிறுவனம்புற்றுநோயியல் பார்மா

Oncology Pharma Inc : Oncology Pharma Signs License Agreement for mRNA Intellectual Property As It Reveals Strategic Plans for Treating Pancreatic Cancer

(1) SAN FRANCISCO, CA / ACCESSWIRE / April 7, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) signed a license agreement with Regen BioPharma Inc. for intellectual property pertaining to mRNA to be used in developing a therapy for treating pancreatic cancer. This license agreement expands the Company s portfolio of intellectual property that It plans to develop for niche biotechnology markets. Oncology Pharma issued a statement We are looking to expand our presence in the cancer therapy market. This showcases our commitment to developing quality therapies to make patients lives better. A spokesperson for the Company said the company believes this is a major milestone for the company and is evidence of it achieving its goals in brand development.

San franciscoUnited statesKostenloser wertpapierhandelRegen biopharma incOncology pharma incOncology pharmaRegen biopharmaAdvisory boardSansome streetசான் பிரான்சிஸ்கோஒன்றுபட்டது மாநிலங்களில்புற்றுநோயியல் பார்மா இன்க்புற்றுநோயியல் பார்மா

Oncology Pharma Signs License Agreement for mRNA Intellectual Property As It Reveals Strategic Plans for Treating Pancreatic Cancer

Oncology Pharma Signs License Agreement for mRNA Intellectual Property As It Reveals Strategic Plans for Treating Pancreatic Cancer
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesRegen biopharma incOncology pharma incOncology pharmaRegen biopharmaAdvisory boardSansome streetசான் பிரான்சிஸ்கோஒன்றுபட்டது மாநிலங்களில்புற்றுநோயியல் பார்மா இன்க்புற்றுநோயியல் பார்மா